"BRAF mutation" trang 1 - tải miễn phí từ tailieunhanh
The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
12    80    1
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
5    66    1
A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: The NEW BEACON study

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: The NEW BEACON study
6    8    1
Research on clinical characteristics, immunohistochemistry and mutation of BRAF gene in patients with thyroid carcinoma

Research on clinical characteristics, immunohistochemistry and mutation of BRAF gene in patients with thyroid carcinoma
9    80    0
Summary of Medical Doctoral thesis: Histopatholoy, immunohistochemistry, BRAF V600E mutation in recurrent, metastatic differentiated thyroid carcinoma

Summary of Medical Doctoral thesis: Histopatholoy, immunohistochemistry, BRAF V600E mutation in recurrent, metastatic differentiated thyroid carcinoma
27    71    1
Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
9    46    1
The clinical response to vemurafenib in a patient with a rare BRAFV600DK601 del mutation-positive melanoma

The clinical response to vemurafenib in a patient with a rare BRAFV600DK601 del mutation-positive melanoma
8    82    1
Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay

Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay
9    84    0
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
9    50    1
Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages

Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
9    46    1
Báo cáo hóa học:

Báo cáo hóa học: " Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032"
3    51    0
Expression and clinical significance of PDL1 and BRAF expression in nasopharyngeal carcinoma

Expression and clinical significance of PDL1 and BRAF expression in nasopharyngeal carcinoma
8    62    0
Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: A case report

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: A case report
4    86    0
Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
11    70    1
Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status

Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status
13    35    1
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: Implications for sensitivity and resistance

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: Implications for sensitivity and resistance
9    32    1
Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer

Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
7    66    1
Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: A multicenter retrospective study

Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: A multicenter retrospective study
11    2    1
PIK3CA amplification is common in left side tubular adenomas but uncommon sessile serrated adenomas exclusively with KRAS mutation

PIK3CA amplification is common in left side tubular adenomas but uncommon sessile serrated adenomas exclusively with KRAS mutation
5    77    0
Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation
8    23    1